Open AccessEndostatin a Potential Biomarker for Heart Failure with Preserved Ejection Fraction
Author(s) -
Michael Coll Barroso,
Philip Boehme,
Frank Krämer,
Thomas Mussack,
Till Koehler,
Jan-Erik Gülker,
Martin Karoff,
Wilfried Dinh
Publication year - 2017
Publication title -
arquivos brasileiros de cardiologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 53
eISSN - 1678-4170
pISSN - 0066-782X
DOI - 10.5935/abc.20170144
Subject(s) - endostatin , medicine , heart failure , ejection fraction , heart failure with preserved ejection fraction , cardiology , interquartile range , natriuretic peptide , diastole , asymptomatic , biomarker , angiogenesis , blood pressure , biochemistry , chemistry
Endostatin is a circulating endogenous angiogenesis inhibitor preventing neovascularization. Previous studies demonstrated the prognostic value of Endostatin among patients with heart failure with reduced ejection fraction (HFrEF). However, the role of Endostatin among patients with heart failure with preserved ejection fraction (HFpEF) remains unclear.